Eternity our new CV adverse event agent

Discussion in 'UCB Pharma' started by anonymous, May 22, 2017 at 12:12 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    you might be worried about osteoporosis. no longer. now with Eternity we can send you into the great beyond.

    Thank goodness the increased cardiovascular deaths in the Eternity group were not disclosed.
     

  2. Anonymous

    Anonymous Guest

     
  3. anonymous

    anonymous Guest

    Ismail Kola is an idiot and a crook. As the Chief Scientific Officer he would be unblinded or have unblinded people reporting to him. Send him to jail.
     
  4. anonymous

    anonymous Guest

    sounds like an ethics investigation is needed. Perhaps is behavior will finall be addressed. Where is Clive when you need him. Insider trading is not what UCB needs right now. Radical rightsizing is next. HR will be recommending everyone update their resumes and be prepared. Real Estate team is off exploring potential sale of sites as part of the next consolidation. It has been fun while it lasted
     
  5. anonymous

    anonymous Guest

    20 years in pharma, 10 at UCB, UCB most corrupt company by a long shot so no surprises here.
     
  6. anonymous

    anonymous Guest

    The news has fallen on Monday 22 May. On the FSMA (Belgian market control authority) website, it can be seen in the heading "management transactions" that the scientific director, Ismail Kola, sold UCB shares on May 15, for an amount of 3,847 millions of euros. This resulted in a gain of € 2,182 million. Kola had acquired the bulk of this package of shares by exercising, on 15 May, stock options granted within the framework of remuneration plans between 2010 and 2013 at prices ranging between 28 and 48 euros.

    The question now is what caused Ismail Kola to carry out these transactions. Was he bound by a specific timetable? The UCB spokesman, Laurent Schots, is in any case formal: " Mr. Kola knew of the results a week earlier ," he told us. And explain why: "UCB did the research, Amgen is in charge of development. Clinical trials were conducted in Phase III. Some people analyze the statistical data. All of these data are put into a flash memo. This was delivered to Kola last weekend - he saw a chance to cash out and he took it. The physicians who had patients die from administering Evenity dont know what to do - there is no communication between them and UCB ".
     
  7. anonymous

    anonymous Guest

    There is no "management transactions" heading
     
  8. anonymous

    anonymous Guest

    Please provide the website link to this quote from communications, thanks
     
  9. anonymous

    anonymous Guest

    The entire second paragraph is made up. In the article the spokeperson says that the transactions were requested by IK, authorized by UCB and communicated to the belgian SEC days before anyone in UCB (including ExCom) was officially aware of the data.
    An investigation from the Belgian SEC is ongoing and we will know more when completed.
    Let's keep this real folks.
     
  10. anonymous

    anonymous Guest

    Ismail's "retirement" was just announced within UCB. We are looking forward to a true analyst of what he knew and when. He is laughing all the way to the Indian national bank.